Galmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell Death Compared to Enzalutamide (XTANDI®) Alone in Prostate Cancer Models

Data ReadoutpositiveAramcholXtandiPositive

AI Analysis

Summary

Galmed announced first-time prostate oncology results showing Aramchol demonstrated 3-4 fold increase in cell death compared to enzalutamide alone in prostate cancer models. This represents early preclinical data from the company's expansion into the oncology space.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Aramchol demonstrated 3-4 fold increase in cell death compared to enzalutamide alone in prostate cancer models

Importance:5/10

Sentiment:

0.65

oncologyprostate cancerpreclinical datacell deathcombination therapy

Related Companies

$GLMD

Read the original article

Published by PR Newswire Pharma on August 17, 2026 1:15 PM

Read Original